Strongbridge Biopharma plc (SBBP) financial statements (2021 and earlier)

Company profile

Business Address 900 NORTHBROOK DRIVE, SUITE 200
TREVOSE, PA 19053
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:887812258
Cash and cash equivalents885712258
Other undisclosed cash, cash equivalents, and short-term investments 21  
Receivables3222
Inventory, net of allowances, customer advances and progress billings1241
Inventory1241
Other undisclosed current assets1141
Total current assets:928413261
Noncurrent Assets
Operating lease, right-of-use asset11
Property, plant and equipment0000
Intangible assets, net (including goodwill)27323742
Goodwill7777
Intangible assets, net (excluding goodwill)20253035
Other noncurrent assets1101
Total noncurrent assets:29343843
TOTAL ASSETS:121118170104
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities10211611
Accrued liabilities3211611
Employee-related liabilities6   
Taxes payable1   
Other undisclosed current liabilities11311
Total current liabilities:21241712
Noncurrent Liabilities
Long-term debt and lease obligation18  38
Long-term debt, excluding current maturities17  38
Operating lease, liability1 
Liabilities, other than long-term debt11  
Other liabilities11  
Other undisclosed noncurrent liabilities16204066
Total noncurrent liabilities:342140103
Total liabilities:554557116
Stockholders' equity
Stockholders' equity attributable to parent6672113(12)
Common stock1110
Additional paid in capital370332323231
Accumulated other comprehensive income 0  
Accumulated deficit(306)(260)(211)(243)
Other undisclosed stockholders' equity0000
Total stockholders' equity:6672113(12)
TOTAL LIABILITIES AND EQUITY:121118170104

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues3122187
Revenue, net7
Cost of revenue(2)(4)(4)(1)
Cost of goods and services sold(2)(4) (1)
Gross profit:2918146
Operating expenses(72)(85)(96)(79)
Operating loss:(43)(67)(82)(74)
Nonoperating income (expense)(2)19114(38)
Investment income, nonoperating  131 
Interest and debt expense(1) (21)(4)
Income (loss) from continuing operations before equity method investments, income taxes:(46)(48)11(115)
Other undisclosed income from continuing operations before income taxes1 214
Income (loss) from continuing operations before income taxes:(45)(48)32(112)
Income tax expense (benefit)0(2)(1)(2)
Net income (loss) available to common stockholders, basic:(45)(49)32(113)
Other undisclosed net loss available to common stockholders, diluted (11)(16) 
Net income (loss) available to common stockholders, diluted:(45)(61)16(113)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):(45)(49)32(113)
Comprehensive income (loss):(45)(49)32(113)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)0  
Comprehensive income (loss), net of tax, attributable to parent:(45)(49)32(113)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: